As a growing sector, the Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry contributes in the drug discovery process, giving emphasis on how new technologies have improved effectiveness. As in the current scenario artificial intelligence including machine learning may be considered the future for a wide range of disciplines and industries specially the pharmaceutical industry. As we know today pharmaceutical industries producing a single approved drug cost the company millions with many years of rigorous testing prior to its approval, reducing costs and time is of high interest. The involvement of Artificial Intelligence will be useful to the pharmaceutical industry and also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics.

No abstract

Clotrimazole is a broad-spectrum antimycotic drug, Candida albicans as well as other fungal infections are typically treated with this drug. “Clinical clotrimazole seems to be a topical therapy treating tineapedis (athlete's foot), vulvovaginal candidiasis, and oropharyngeal candidiasis.” That is a synthetic azole antimycotic. It inhibits fungal growth by decreasing the production of ergosterol. Clotrimazole has become a medication of interest for a variety of illnesses, including sickle cell anaemia, malaria, and some cancers, in addition to its antimycotic properties. It's been mixed with other molecules as well, to create clotrimazole compounds with enhanced pharmacological effectiveness, including such metals. Numerous novel pharmaceutical formulations enabling variable releases are also being developed. Clotrimazole is a well-tolerated, little-adverse drug, however certain immune compromised individuals are developing treatment resistance. Clotrimazole's pharmaceutical chemistry, use, and pharmacology are discussed in this study.

No abstract

Nano emulsions formulated for the ocular drug delivery have a good scope in pharmaceutical products due to the transparency at enlarged droplet volume fraction, advanced rate of bioavailability and improved shelf life. In this study we aim to prepare & evaluate moxifloxacin nano emulsion of for ocular delivery that will result with improved drug retention in cornea, sustained release will be achieved and dosing frequency will be reduced as compared with conventional products. Drug identification was done by UV FTIR, melting point and solubility. Nano emulsion were prepared by standard procedure with minor modifications. Particle size was found around 380 nm by Malvern analyser. SEM showed droplets of spherical shape and size 300 nm. % entrapment was 81 %. Microscopy also showed drops oval to spherical in shape. Marketed formulation released 100 % within 30 min where as optimized nano emulsion was released in sustained manner for more than 6 hrs. Thus it can be concluded that designed formulation can be able to improve drug activity.